Vaxcyte earnings were -$463.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest PCVX earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$137.1M, up 32.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PCVX reported annual earnings of -$463.9M, with 15.3% growth. The next PCVX earnings date is May 6, 2025.
On PCVX's earnings call on Invalid Date, Vaxcyte (NASDAQ: PCVX) reported Q4 2024 earnings per share (EPS) of -$1.02, up 43.96% year over year. Total PCVX earnings for the quarter were -$137.08 million. In the same quarter last year, Vaxcyte's earnings per share (EPS) was -$1.82.
The next PCVX earnings call is Invalid Date. Add PCVX to your watchlist to be reminded of Vaxcyte's next earnings date.
What was PCVX's earnings growth in the past year?
As of Vaxcyte's earnings date in Invalid Date, Vaxcyte's earnings has grown year over year. PCVX earnings in the past year totalled -$463.93 million.
Is Vaxcyte profitable or losing money?
As of the last Vaxcyte earnings report, Vaxcyte is currently losing money. Vaxcyte's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$463.93 million, a 15.33% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.